Healio

Anti-VEGF at forefront of DME, DR management

In this Healio Video Perspective from Retina 2026, Sharon Fekrat, MD, FACS, FASRS, of Duke University, discusses the current ...
Healio

Anti-VEGF patient assistance programs yield vision gains for underinsured patients

Patients with retinal diseases who were treated with anti-VEGF therapies through manufacturer patient assistance programs ...
Targeted Oncology

FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC

Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...
BioSpace

Summit’s Potential Keytruda Rival Gets November FDA Decision Date

The FDA is currently reviewing Summit's PD-1/VEGF bispecific as part of a chemotherapy combo for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer.
MedPage Today

Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer

Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...
MedPage Today

Alternative to Anti-VEGF Shows Safety, Efficacy in Diabetic Macular Edema

A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The drug also showed potential efficacy in patients who failed to optimally ...